Piper Jaffray & Co. initiates coverage on BioMarin Pharmaceutical (Nasdaq: BMRN) with a Neutral. Price target …
While Merck & Co. Inc. and others are impressing Wall Street and investors with their cancer-fighting drugs, BioMarin Pharmaceuticals is finding that expectations are growing lofty — and failure to meet them could prove hazardous to …
Alas for the longs, it was not, as the stock reluctantly trudged from $63 to $70. What's wrong with $7 in a few days, you ask? Nothing, of course, unless one considers that such a move doesn't even begin to scratch the surface of how …
10 stocks we like better than BioMarin Pharmaceutical When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the …
CEO Jean Jacques Bienaime sold 120,000 shares of BMRN stock on 10/28/2016 at the average price of $81.3. The price of the stock has decreased by 0.96% since. CEO Jean Jacques Bienaime sold 41,666 shares of BMRN stock on …
The tremendous potential for vadadustat could drive this biotech stock much higher. Many investors are at least somewhat aware of BioMarin. The biotech claims five products on the market treating rare diseases. However, I think some still …
BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported a loss of $16.3 million in its first quarter. The San Rafael, California-based company said it had a loss of 9 cents per share. Earnings, adjusted for stock option expense and non …
Yahoo!8mon
BioMarin Pharmaceutical, Inc. (BMRN), a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times Square in celebration of the …
Biomarin Pharmaceutical Inc : Biomarin announces public offering of common stock .Says offering of 7.5 million shares of its common stock in an underwritten public offering.
AUSTIN (KXAN) – Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday ... s meeting in New York about how the decision might affect stock prices. Sloan, who has battled ovarian cancer for seven …